| Code | CSB-RA7153MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Seniprutug, targeting TRBV9 (T-cell receptor beta variable 9), a specific variable region segment of the T-cell receptor beta chain. TRBV9 is one of the functional variable gene segments that contributes to TCR diversity through V(D)J recombination, enabling T cells to recognize a wide array of antigenic peptides presented by MHC molecules. The expression and clonal expansion of TRBV9-containing T cells have been implicated in various immune-mediated conditions and autoimmune diseases, where specific T-cell populations play pathogenic roles in disease progression.
Seniprutug represents an investigational therapeutic antibody developed to selectively deplete or modulate TRBV9-expressing T-cell populations. This biosimilar provides researchers with a valuable tool for investigating TRBV9-mediated immune responses, studying T-cell repertoire dynamics, and exploring therapeutic strategies targeting pathogenic T-cell clones in autoimmune and inflammatory disorders. The antibody enables detailed characterization of TRBV9+ T-cell subsets and their functional roles in immune homeostasis and disease pathology.
There are currently no reviews for this product.
HGNC: 12246